Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Structure Therapeutics Inc.GPCR · Entity 1222 | CHIEF MEDICAL OFFICER | March 15, 2024 | March 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Structure Therapeutics Inc.
Report date March 15, 2024 · Filed March 20, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.75 · Expires 2034-03-14 | Direct | 65,352 |
Reported balance
After 2024-03-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 65,352 · Balance 65,352 F1: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F2: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
F2: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 16:46 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantStock Option (right to buy) · Derivative | 65,352 | $0.00 Strike: $35.25 | $0.00 |
DisclosureSEC source: 0001415889-24-008567 · form4-03192024_080323.xml · derivative · entry 2 Bach Mark Allen · CIK 0001962610 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,352 Underlying: Ordinary Shares · 65,352 shares Expires 2034-03-14 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 16:46 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantOrdinary Shares | 26,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008567 · form4-03192024_080323.xml · nonDerivative · entry 1 Bach Mark Allen · CIK 0001962610 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,235 F1 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 19:41 UTC Amendment | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantStock Option (right to buy) · Derivative | 65,352 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001415889-24-008783 · form4a-03202024_110306.xml · derivative · entry 1 Bach Mark Allen · CIK 0001962610 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,352 Underlying: Ordinary Shares · 65,352 shares Expires 2034-03-14 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | PurchaseAmerican Depositary Shares · Derivative | 1,500 | $15.00 | $22,500.00 |
DisclosureSEC source: 0001209191-23-008163 · doc4.xml · derivative · entry 1 Bach Mark Allen · CIK 0001962610 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Ordinary Shares · 4,500 shares Expires not disclosed F1 · derivative.exercise_price: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F2 · kind: The American Depositary Shares were purchased in the Issuer's initial public offering. F1 · derivative.exercise_date: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F1 · derivative.expiration_date: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.